Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.73 |
| ▸ | HTR2A | P28223 | 12/20 | 0.73 |
| ▸ | HTR2B | P41595 | 7/20 | 0.73 |
| ▸ | HTR7 | P34969 | 6/20 | 0.71 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 4/20 | 0.58 |
| ▸ | HTR1D | P28221 | 4/20 | 0.58 |
| ▸ | HTR5A | P47898 | 4/20 | 0.58 |
| ▸ | HTR6 | P50406 | 4/20 | 0.58 |
| ▸ | HTR1B | P28222 | 3/20 | 0.58 |
| ▸ | HTR1E | P28566 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | HTR3A | P46098 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725785 | 0.91 | HTR2C (0.73) | HTR2CHTR2AHTR2BHTR7CHRM4 | |
| SCHEMBL22493142 | 0.82 | HTR2A (0.62) | HTR2CHTR2AHTR2BHTR7CHRM4 | |
| SCHEMBL538174 | 0.82 | HTR7 (0.76) | HTR2CHTR2AHTR2BHTR7CHRM4 | |
| SCHEMBL6782129 | 0.81 | HTR7 (0.82) | HTR2CHTR2AHTR2BHTR7CHRM4 | |
| SCHEMBL6407779 | 0.79 | KMT2A (0.82) | HTR2CHTR2AHTR2BHTR7KMT2A | |
| SCHEMBL6779743 | 0.79 | KMT2A (0.68) | HTR2CHTR2AHTR2BHTR7DRD2 | |
| SCHEMBL763727 | 0.77 | HTR7 (0.72) | HTR2CHTR2AHTR2BHTR7CHRM4 | |
| SCHEMBL765058 | 0.77 | HTR7 (0.72) | HTR2CHTR2AHTR2BHTR7CHRM4 | |
| SCHEMBL17760604 | 0.76 | KDM4E (0.70) | KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL17624908 | 0.76 | KDM4E (0.70) | KMT2AMEN1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| CN-106167488-A | Treatment cancer and the method for non-neoplastic conditions | PTC医疗公司 | 2016-11-30 | — | — | CN | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8697662-B2 | Methods for treating Kaposi sarcoma | PTC THERAPEUTICS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-6720331-B2 | HAVING ANTI-MITOTIC ACTIVITY FOR THERAPY OF CANCER | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2004-04-13 | — | — | US | disclosed |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | NATIONAL SUN YAT-SEN UNIVERSITY (TW) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157402-A1 | METHODS FOR TREATING BRAIN TUMORS | HDGF, VEGFA, FLT4 | HTR2C 2942/4885HTR2A 2162/4885HTR2B 2079/4885 |
| US-20030040527-A1 | 1-substituted 1,2,3,4-tetrahydro-beta-carboline and 3,4-dihydro-beta-carboline and analogs as antitumor agents | DCK, CCR1, CCNT1 | HTR2C 503/4885HTR2A 1693/4885HTR2B 1017/4885 |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR2C 4502/4885HTR2A 4573/4885HTR2B 4609/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR2C 4500/4885HTR2A 4569/4885HTR2B 4616/4885 |
| US-20120202763-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR2C 4500/4885HTR2A 4569/4885HTR2B 4616/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | HTR2C 4500/4885HTR2A 4569/4885HTR2B 4616/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | HTR2C 4375/4885HTR2A 4541/4885HTR2B 4216/4885 |
| US-20120157401-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | VHL, NGF, VEGFA | HTR2C 4305/4885HTR2A 3401/4885HTR2B 3555/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | HTR2C 4506/4885HTR2A 4610/4885HTR2B 4572/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | HTR2C 4485/4885HTR2A 4597/4885HTR2B 4322/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | HTR2C 4658/4885HTR2A 4437/4885HTR2B 4514/4885 |
| US-20120202801-A1 | METHODS FOR TREATING BREAST CANCER | VEGFA, FLT4, FLT1 | HTR2C 3899/4885HTR2A 3764/4885HTR2B 3434/4885 |
| US-20120178707-A1 | METHODS FOR TREATING PROSTRATE CONDITIONS | ACP3, BPHL, PTGFR | HTR2C 2930/4885HTR2A 2682/4885HTR2B 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.